Allergy Therapeutics plc (AIM:AGY)

Allergy Therapeutics Balance Sheet

Financials in millions GBP. Fiscal year is July - June.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Cash & Equivalents	10.08	12.79	12.92	14.85	20.52	40.27
Cash & Short-Term Investments	10.08	12.79	12.92	14.85	20.52	40.27
Cash Growth	-53.48%	-0.97%	-13.00%	-27.64%	-49.06%	8.96%
Accounts Receivable	10.98	2.85	2.86	2.37	2.69	2.96
Other Receivables	1.4	3.19	3.35	2.69	3.21	1.66
Receivables	12.38	6.03	6.21	5.06	5.91	4.62
Inventory	13.79	13.92	12.74	11.59	11.41	10.84
Prepaid Expenses	-	1.94	1.62	2.03	4.56	1.6
Other Current Assets	-	-	-	-	-	0.53
Total Current Assets	36.25	34.68	33.48	33.53	42.39	57.86
Property, Plant & Equipment	26.39	24.26	23.75	23.24	20.19	19.72
Goodwill	3.34	3.33	3.32	3.35	3.35	3.34
Other Intangible Assets	0.86	0.93	1.37	1.79	1.69	1.41
Long-Term Deferred Tax Assets	1.39	1.51	1.58	-	-	-
Other Long-Term Assets	2.78	2.84	2.91	4.87	5.33	5.76
Total Assets	71	67.54	66.41	66.77	72.95	88.09

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Accounts Payable	13.95	4.49	4.01	4.09	4.28	2.9
Accrued Expenses	-	8.1	8.65	12.49	11.34	13.55
Current Portion of Long-Term Debt	0.45	0.41	0.6	0.65	0.95	0.96
Current Portion of Leases	1.51	1.48	1.52	1.16	1.32	0.79
Current Income Taxes Payable	1.3	0.91	1.43	-	-	-
Other Current Liabilities	14.82	11.81	2.59	0.18	0.16	0.03
Total Current Liabilities	32.03	27.19	18.8	18.57	18.05	18.23
Long-Term Debt	19.71	53.04	22.5	26.44	1.5	2.45
Long-Term Leases	5.08	5.17	6.37	7.75	6.76	6.97
Pension & Post-Retirement Benefits	8.23	8.59	8.61	7.92	8.32	11.29
Long-Term Deferred Tax Liabilities	0.05	0.07	0.06	0.45	0.41	0.41
Other Long-Term Liabilities	1.66	1.68	2.71	3.58	0.14	0.21
Total Liabilities	66.76	95.74	59.05	64.7	35.18	39.55

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Common Stock	6.14	4.77	4.77	0.68	0.64	0.64
Additional Paid-In Capital	208.13	154.64	154.64	119.03	112.58	112.58
Retained Earnings	-254.34	-235.23	-195.28	-161.87	-118.54	-107.4
Comprehensive Income & Other	44.32	47.63	43.23	44.23	43.09	42.72
Shareholders' Equity	4.25	-28.19	7.36	2.07	37.77	48.54
Total Liabilities & Equity	71	67.54	66.41	66.77	72.95	88.09

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Total Debt	26.75	60.09	30.99	35.99	10.53	11.17
Net Cash (Debt)	-16.67	-47.3	-18.07	-21.14	9.99	29.1
Net Cash Growth	-	-	-	-	-65.69%	17.42%
Net Cash Per Share	-0.00	-0.01	-0.00	-0.03	0.02	0.04
Filing Date Shares Outstanding	6,141	4,766	4,766	679.1	644.1	641.77
Total Common Shares Outstanding	6,141	4,766	4,766	679.1	644.1	641.77
Working Capital	4.22	7.49	14.68	14.96	24.34	39.63
Book Value Per Share	0.00	-0.01	0.00	0.00	0.06	0.08
Tangible Book Value	0.05	-32.45	2.67	-3.07	32.73	43.78
Tangible Book Value Per Share	0.00	-0.01	0.00	-0.00	0.05	0.07
Land	-	3.14	3.01	3.05	3.08	3.09
Machinery	-	40.29	36.96	33.68	29.66	27.35

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 14, 2026

Data Sources Report a data error